Dyne Therapeutics Launches $200M Common Stock Public Offering | DYN Stock News - Stock Titan
Yesterday • Google News
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Yesterday • Google News
16 hours ago • Google News